National Pharmacy Health & Leadership Alliance Verify a MemberMember Login
NPHLANational Pharmacy Health & Leadership Alliance
Apply for Membership

02RegulatoryWhat Changed Today

What changed today in Regulatory: 1 recall record

Every new official record on the Pharmacy, Compounding & Regulatory Intelligence desk since this morning, each linked to its primary source.

By NPHLA IntelligencePublished Automated from official records

The signal

NPHLA tracked 1 new official record on this desk today: 1 recall record.

Why this matters

Federal Register documents and FDA notices can change compliance obligations, deadlines and enforcement priorities for pharmacies, compounders and prescribers.

What changed

  1. Class II: Tirzepatide/Niacinamide 2mL vial (40 MG per Vial) Inj 20mg/2mg/mL, RX Only, Houston RX LLC, 15430 Vantage Parkway E STE 220, Houston, TX… — reason given: Lack of assurance of sterility. (firm: Houston Rx LLC).[1]
  2. Also reported by BioPharma Dive: “Novel protein and peptide therapeutics”.[2]

Who this affects

  • Pharmacies
  • 503A compounders
  • 503B outsourcing facilities
  • Pharmacists
  • Prescribers
  • Practice owners & operators

Jurisdictions: Texas.

What to watch next

No new verified deadlines in today’s records. See Deadline Watch for upcoming dates.

NPHLA takeaway

These are factual summaries of official records with no interpretation. Open the primary documents for full details; NPHLA editors add analysis where developments warrant it.

Source file

  1. [1]
  2. [2]
    Novel protein and peptide therapeutics

    News reportingBioPharma DiveIndustry coverage — headline and link only

Compiled automatically from primary official sources and peer-reviewed literature. Each line is a factual summary of a public record, linked to it — no interpretation is added. NPHLA links to sources and does not republish their text. Professional information only — not medical, legal or regulatory advice for any individual situation. Our standards.